Physician profile
Michael D Mcphee
NPI 1285685495
$11,800.16
in general payments reported to CMS, 2019-2025
13 companies · $9,091 in 2025
The $9,091 reported for 2025 was more than what 93% of Surgical Oncology providers received nationally (typical 2025 total: $288).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $105 · 2024: $2,604 · 2025: $9,091.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,459 · Travel and Lodging: $3,044 · Food and Beverage: $1,633 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,104 · Consulting Fee: $455.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,459.00 |
| Travel and Lodging | $3,043.67 |
| Food and Beverage | $1,633.02 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,104.00 |
| Consulting Fee | $455.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kerecis Limited | $11,099.57 | 2024-2025 | Kerecis Surgiclose, Kerecis Omega3 Marigen, Kerecis Graftguide |
| Organogenesis INC. | $283.27 | 2024-2025 | Novachor, Cygnus Dual, Affinity |
| Solventum Corporation | $187.37 | 2024-2025 | Activ.A.C. |
| Regeneron Healthcare Solutions, INC. | $56.53 | 2019-2024 | Libtayo |
| Vanda Pharmaceuticals INC. | $34.45 | 2019 | |
| Iovance Biotherapeutics, INC. | $33.05 | 2024-2025 | Amtagvi |
| Genentech USA, INC. | $22.00 | 2019 | |
| Fidia Pharma USA INC. | $20.07 | 2025 | |
| Mimedx Group, INC. | $15.09 | 2025 | |
| Almirall LLC | $14.27 | 2024 | Klisyri |
| Tactile Systems Technology INC | $11.63 | 2019 | |
| Merck Sharp & Dohme LLC | $11.57 | 2019 | |
| Reprise Biomedical, INC. | $11.29 | 2025 | Miro3d |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Mcphee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.